Top
image credit: Adobe Stock

Mayo Clinic, Hibiscus BioVentures and Innoforce Launch Mayflower Cell and Gene Therapy Accelerator

August 31, 2022

Mayo Clinic, Hibiscus BioVentures and Innoforce Pharma have launched Mayflower BioVentures, a cell and gene therapy accelerator dedicated to identifying and forming companies around technologies that address unmet patient needs. This academic and industry relationship will establish independent cell and gene therapy companies to advance the development of Mayo Clinic technologies through preclinical and early feasibility studies.

With a shared interest in identifying treatments and preventing disease, the aim of Mayflower is to advance new cures for serious and complex conditions through cell and gene therapies.

Read More on Contract Pharma